Company news
Novamind Inc news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Novamind to Present at Benzinga Healthcare Conference
September 29, 2021
Novamind Announces DTC Eligibility for its Common Shares
September 24, 2021
Novamind to Present at Benzinga Healthcare Conference
September 23, 2021
Novamind Announces Inclusion in NYSE Listed AdvisorShares Psychedelics ETF
September 20, 2021
Novamind to Present at Life Sciences Investor Forum
September 14, 2021
Novamind to Serve as Research Site for Karuna Therapeutics Late-Stage Clinical Trial
September 13, 2021
Novamind Uplists to OTCQB Venture Market
September 9, 2021
Novamind to Present at H.C. Wainwright 23rd Annual Global Investment Conference
September 8, 2021
Novamind Divests Non-Core Retreat Investment
August 11, 2021
Novamind Strengthens Mental Health Expertise, Adds Communications Leader
August 6, 2021
Novamind Opens 5th Clinic Location Specialized in Integrative Psychiatry for Patients with Treatment-Resistant Conditions
July 29, 2021
Novamind Has Applied to Have its Common Shares Posted for Trading on the OTCQB in the United States
July 21, 2021
Novamind Selected as Research Site for Bionomics' PTSD Clinical Trial
July 8, 2021
Novamind Launches Psychedelic Therapy Frontiers Podcast
June 30, 2021
Novamind Welcomes Dr. Paul Thielking as Chief Scientific Officer
June 23, 2021
Novamind Announces US$1,000,000 Strategic Investment in Stealth Mode Drug Development Company
June 17, 2021
Novamind to Present at the H.C. Wainwright Psychedelics Conference on June 17, 2021
June 15, 2021
Novamind Launches Psychedelic Therapy Protocol for Frontline Healthcare Workers
June 10, 2021
Novamind Reports Fiscal Q3 Financial Results and Operating Highlights
June 1, 2021
Novamind Opens Client Care Center to Support High Demand for Treatments
May 18, 2021
Novamind Doubles in Size, Adds Four New Psychedelic Mental Health Clinics
May 4, 2021
Novamind Collaborates with Center for Change
April 21, 2021
Novamind Announces Participation at the Planet MicroCap Showcase on April 20 - 22, 2021
April 20, 2021
Novamind to Present at the Planet MicroCap Virtual Event on April 22, 2021
April 19, 2021
Novamind Increases Strategic Investment in Bionomics
April 13, 2021
Novamind to Present at Benzinga Biotech Conference
March 24, 2021
Novamind to Present at Benzinga Biotech Conference
March 22, 2021
Novamind Partners with Merck for New Treatment-Resistant Depression Trial
March 18, 2021
Novamind Expands Leadership Team, Accelerating M&A
March 3, 2021
Novamind Reports Company Highlights and Strong Revenue Growth in Fiscal Second Quarter
March 1, 2021
Novamind to Present at Benzinga Conference
February 24, 2021
Novamind to Present at Benzinga Conference
February 23, 2021
Novamind Fast Tracked for Inclusion in Horizons Psychedelic ETF
February 22, 2021
Novamind Announces Symbol Change on OTC Market To "NVMDF"
February 19, 2021
Novamind Announces Strategic Investment in Bionomics to Support PTSD Clinical Trial
February 11, 2021
Novamind to Present at Canaccord Genuity Conference: "New Paradigms & Treatment Approaches in Mental Health"
January 29, 2021
Novamind Reaches Major Milestones for Ketamine and Spravato(TM) Treatments
January 28, 2021
Novamind Announces Marketing Services Agreements
January 26, 2021
Novamind to Present at Inaugural KCSA Psychedelics Investor Conference
January 25, 2021
Former LifeLabs COO Joins Novamind Leadership Team
January 19, 2021
Novamind Expands Psychedelic Medicine Access in Utah
January 13, 2021
Novamind Appoints Chuck Rifici to its Board of Directors
January 8, 2021
Decks
- Investor Presentation (November 2021)
Investor deck · 23 slides · Nov 29, 2021